Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP -0.75%77 EV-to-OCF is -34.72 as of Aug. 24, 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 77/100 and a GF Value™ of €2.63 (Fairly Valued). The stock has 3 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Biohit Oyj ranks better than 91.06% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Biohit Oyj's Enterprise Value is €38.19 Mil.
Biohit Oyj's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.10 Mil. Therefore, Biohit Oyj's EV-to-OCF for today is -34.72.
The historical rank and industry rank for Biohit Oyj's EV-to-OCF or its related term are showing as below:
LTS:0DRP'
s EV-to-OCF Range Over the Past 10 Years
Min: -1264.64 Med: -30.18 Max: 643.21
Current: -34.72
During the past 13 years, the highest EV-to-OCF of Biohit Oyj was 643.21. The lowest was -1264.64. And the median was -30.18.
LTS:0DRP's EV-to-OCF is ranked better than 91.06% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.695
vs LTS:0DRP: -34.72
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biohit Oyj's share price for today is €2.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biohit Oyj EV-to-OCF Related Terms
Biohit Oyj EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's EV-to-OCF falls into.
Biohit Oyj's current Enterprise Value is €38.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biohit Oyj's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a EV-to-OCF of -34.72 as of Aug. 24, 2026. According to the industry distribution chart, Biohit Oyj ranks #76 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is Biohit Oyj's EV-to-OCF too high?
Biohit Oyj's current EV-to-OCF is -34.72. Based on the distribution chart, Biohit Oyj ranks #76 out of 850 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #76 out of 850 companies for EV-to-OCF. This places Biohit Oyj in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.70, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current EV-to-OCF is -34.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.63, compared to a current price of €2.65 — trading 0.8% above its estimated fair value. The current EV-to-OCF is -34.72. Biohit Oyj's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current EV-to-OCF is -34.72 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.65 is trading 0.8% above its estimated GF Value™ of €2.63.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
EV-to-OCF: -34.72
GF Value™: €2.63 vs. price of €2.65 (0.8% above fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
77GF Score
Get the complete analysis for LTS:0DRP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
